HK1220449A1 - 治疗氧化应激障碍的试卤灵衍生物 - Google Patents

治疗氧化应激障碍的试卤灵衍生物 Download PDF

Info

Publication number
HK1220449A1
HK1220449A1 HK16108425.0A HK16108425A HK1220449A1 HK 1220449 A1 HK1220449 A1 HK 1220449A1 HK 16108425 A HK16108425 A HK 16108425A HK 1220449 A1 HK1220449 A1 HK 1220449A1
Authority
HK
Hong Kong
Prior art keywords
oxidative stress
treatment
stress disorders
disorders
resorufin derivatives
Prior art date
Application number
HK16108425.0A
Other languages
English (en)
Chinese (zh)
Inventor
Andrew W. Hinman
Dana Davis
William D. Shrader
Original Assignee
Bioelectron Technology Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioelectron Technology Corporation filed Critical Bioelectron Technology Corporation
Publication of HK1220449A1 publication Critical patent/HK1220449A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C07D265/38—[b, e]-condensed with two six-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Nutrition Science (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
HK16108425.0A 2013-03-15 2014-03-14 治疗氧化应激障碍的试卤灵衍生物 HK1220449A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13/837,872 US9296712B2 (en) 2013-03-15 2013-03-15 Resorufin derivatives for treatment of oxidative stress disorders
US13/837,872 2013-03-15
PCT/US2014/029809 WO2014145118A1 (en) 2013-03-15 2014-03-14 Resorufin derivatives for treatment of oxidative stress disorders

Publications (1)

Publication Number Publication Date
HK1220449A1 true HK1220449A1 (zh) 2017-05-05

Family

ID=50629004

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16108425.0A HK1220449A1 (zh) 2013-03-15 2014-03-14 治疗氧化应激障碍的试卤灵衍生物

Country Status (6)

Country Link
US (1) US9296712B2 (enExample)
EP (1) EP2970238A1 (enExample)
JP (1) JP2016515527A (enExample)
CA (1) CA2906150A1 (enExample)
HK (1) HK1220449A1 (enExample)
WO (1) WO2014145118A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2564843B1 (en) 2005-06-01 2018-12-26 Bioelectron Technology Corporation Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
DK2220030T3 (en) 2007-11-06 2016-04-11 Edison Pharmaceuticals Inc 4- (P-QUINONYL) -2-HYDROXYBUTANAMIDDERIVATER TO TREAT mitochondrial
EP2237664A4 (en) 2008-01-08 2013-05-22 Edison Pharmaceuticals Inc (HET) ARYL-p-CHINONE DERIVATIVES FOR THE TREATMENT OF OCHONDRIAL DISEASES
MX363223B (es) 2008-09-10 2019-03-15 Bioelectron Tech Corp Tratamiento de trastornos generalizados del desarrollo con terapeuticos con actividad redox.
ES2553557T3 (es) 2008-10-28 2015-12-10 Edison Pharmaceuticals, Inc. Proceso para la producción de alfa-tocotrienol y derivados
PL2424495T3 (pl) 2009-04-28 2018-06-29 Bioelectron Technology Corporation Leczenie dziedzicznej neuropatii nerwów wzrokowych lebera i dominującego zaniku nerwu wzrokowego chinonami tokotrienolu
US9464016B2 (en) 2011-06-14 2016-10-11 Edison Pharmaceuticals, Inc. Catechol derivatives for treatment of oxidative stress diseases
JP2014520894A (ja) 2011-07-19 2014-08-25 エジソン ファーマシューティカルズ， インコーポレイテッド 非アルファトコトリエノールの存在下でのアルファトコトリエノールの選択的酸化のための方法
EP2892516A1 (en) 2012-09-07 2015-07-15 Edison Pharmaceuticals, Inc. Quinone derivatives for use in the modulation of redox status of individuals
US9670170B2 (en) 2013-03-15 2017-06-06 Bioelectron Technology Corporation Resorufin derivatives for treatment of oxidative stress disorders
US9868711B2 (en) 2013-03-15 2018-01-16 Bioelectron Technology Corporation Phenazine-3-one and phenothiazine-3-one derivatives for treatment of oxidative stress disorders
EP2970158B1 (en) 2013-03-15 2019-02-20 BioElectron Technology Corporation Alkyl-heteroaryl substituted quinone derivatives for treatment of oxidative stress disorders
WO2016070024A1 (en) * 2014-10-31 2016-05-06 Washington University Ddr2 inhibitors and methods of using
PL3233786T3 (pl) 2014-12-16 2022-06-13 Ptc Therapeutics, Inc. Polimorficzne i amorficzne postacie (r)-2-hydroksy-2-metylo-4-(2,4,5-trimetylo-3,6-dioksocykloheksa-1,4-dienylo)butanoamidu
EP3390377A1 (en) 2015-12-16 2018-10-24 BioElectron Technology Corporation Improved methods for enriching alpha-tocotrienol from mixed tocol compositions
WO2017106803A1 (en) 2015-12-17 2017-06-22 Bioelectron Technology Corporation Flouroalkyl, flouroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders
JP2018083799A (ja) 2016-11-15 2018-05-31 バイオエレクトロン テクノロジー コーポレイション ２−置換アミノ−ナフト［１，２−ｄ］イミダゾール−５−オン化合物またはその製薬学上許容される塩
WO2018129411A1 (en) * 2017-01-06 2018-07-12 Bioelectron Technology Corporation Aryl- and heteroaryl-resorufin derivatives for treatment of oxidative stress disorders and liver and kidney disorders
BR112021007153A2 (pt) 2018-10-17 2021-07-20 Ptc Therapeutics, Inc. 2,3,5-trimetil-6-nonilcicloexa-2,5-dieno-1,4-diona para a supressão e tratamento de a-sinucleinopatias, tauopatias e outros distúrbios
WO2023283466A1 (en) 2021-07-08 2023-01-12 Ptc Therapeutics, Inc. Pharmaceutical compositions comprising 2,3,5-trimethyl-6-nonylcyclohexa-2,5-diene-1,4-dione

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE840115L (en) 1983-01-21 1984-07-21 Merck Frosst Canada Inc Phenothiazine derivatives and analogs
US4939145A (en) 1983-01-21 1990-07-03 Merck Frosst Canada, Inc. Phenothiazone derivatives and analogs
US4859667A (en) 1983-01-21 1989-08-22 Merck Frosst Canada, Inc. Pharmaceutical compositions of phenothiazone derivatives and analogs
US4667032A (en) 1983-01-21 1987-05-19 Merck Frosst Canada, Inc. Phenothiazone derivatives and analogs
NZ206795A (en) 1983-01-21 1987-08-31 Merck Frosst Canada Inc Phenothiazines, analogues and pharmaceutical compositions
US4548927A (en) 1983-05-25 1985-10-22 Eaton John W Method and agents for raising animal tolerance to oxidant stress-inducing antibiotics
DE3484745D1 (de) 1983-10-05 1991-08-01 Merck Frosst Canada Inc Inhibitoren fuer die leukotrien-biosynthese.
JPS60209520A (ja) * 1984-03-19 1985-10-22 メルク　エンド　カムパニー　インコーポレーテツド リポキシゲナーゼ阻害剤の細胞保護的使用
EP0155623A3 (en) 1984-03-19 1985-12-27 Merck & Co. Inc. Use of lipoxygenase inhibitors for the preparations of cytoprotective pharmaceutical compostions and process for the preparation of a cytoprotective pharmaceutical composition
DE3644401A1 (de) 1986-12-24 1988-07-07 Boehringer Mannheim Gmbh Neue hydrolase-substrate
DK0801564T3 (da) 1994-12-28 2002-07-15 Janssen Pharmaceutica Nv Anvendelse af nebivolol som et antiatherogent middel
US6232060B1 (en) 1996-01-19 2001-05-15 Galileo Laboratories, Inc. Assay system for anti-stress agents
US5801159A (en) 1996-02-23 1998-09-01 Galileo Laboratories, Inc. Method and composition for inhibiting cellular irreversible changes due to stress
WO2000078296A2 (en) 1999-06-17 2000-12-28 Basf Aktiengesellschaft Tocotrienol and/or tocotrienol derivatives for the treatment or prophylaxis of glutamate- and/or calcium-induced disorders
US6528042B1 (en) 1999-10-08 2003-03-04 Galileo Laboratories, Inc. Compositions of flavonoids for use as cytoprotectants and methods of making and using them
US6426362B1 (en) 1999-10-08 2002-07-30 Galileo Laboratories, Inc. Formulations of tocopherols and methods of making and using them
CA2430415A1 (en) 2000-12-15 2002-06-20 Galileo Laboratories, Inc. Use of tocopherol, metabolites or derivatives thereof or flavonoid metabolites or derivatives thereof in the manufacture of a medicament for the treatment of tissue ischemia
US7034054B2 (en) 2000-12-15 2006-04-25 Galileo Pharmaceuticals, Inc. Methods for the prevention and treatment of cerebral ischemia using non-alpha tocopherols
US6608196B2 (en) 2001-05-03 2003-08-19 Galileo Pharmaceuticals, Inc. Process for solid supported synthesis of pyruvate-derived compounds
NZ513547A (en) 2001-08-13 2002-09-27 Antipodean Biotechnology Ltd Synthesis of triphenylphosphonium quinols (e.g. mitoquinol) and/or quinones (e.g. mitoquinone)
CA2456743A1 (en) 2001-08-21 2003-02-27 Galileo Pharmaceuticals, Inc. Tocopherol enriched compositions and amelioration of inflammatory symptoms
WO2003043570A2 (en) 2001-11-15 2003-05-30 Galileo Laboratories, Inc. Formulations and methods for treatment or amelioration of inflammatory conditions
US6667330B2 (en) 2002-01-31 2003-12-23 Galileo Pharmaceuticals, Inc. Furanone derivatives
US7078541B2 (en) 2002-02-07 2006-07-18 Galileo Pharmaceuticals, Inc. Benzofuran derivatives
MXPA04007550A (es) 2002-02-07 2004-11-10 Galileo Pharmaceuticals Inc Derivados de benzofurano citoprotectores.
US6653346B1 (en) 2002-02-07 2003-11-25 Galileo Pharmaceuticals, Inc. Cytoprotective benzofuran derivatives
GB0204232D0 (en) 2002-02-22 2002-04-10 Isis Innovation Assay
DE60211875T2 (de) 2002-07-01 2006-10-26 Santhera Pharmaceuticals (Schweiz) Ag Screeningverfahren und Verbindungen zur Behandlung von Friedreich ataxia
AU2003287250B9 (en) 2002-10-30 2010-01-28 Ptc Therapeutics, Inc. Identifying therapeutic compounds based on their physical-chemical properties
AU2004226876A1 (en) 2003-04-03 2004-10-14 Prana Biotechnology Ltd Treatment of neurological conditions
US7470798B2 (en) 2003-09-19 2008-12-30 Edison Pharmaceuticals, Inc. 7,8-bicycloalkyl-chroman derivatives
US8710088B2 (en) * 2004-02-11 2014-04-29 Max-Delbruck-Centrum Fur Molekulare Medizin Pharmaceutical and diagnostic compositions for use in the treatment and diagnosis of neurodegenerative diseases or amyloid diseases
US7393662B2 (en) 2004-09-03 2008-07-01 Centocor, Inc. Human EPO mimetic hinge core mimetibodies, compositions, methods and uses
FR2875242B1 (fr) * 2004-09-10 2006-11-17 Biomerieux Sa Nouveaux substrats enzymatiques derives de phenoxazinone et leur utilisation comme revelateur dans la detection de microorganismes a activite peptidase
DE102004046027A1 (de) * 2004-09-21 2006-03-23 Henkel Kgaa Neue direktziehende Farbstoffe
EP2564843B1 (en) 2005-06-01 2018-12-26 Bioelectron Technology Corporation Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
LT1933821T (lt) 2005-09-15 2020-11-10 Ptc Therapeutics, Inc. Šoninės grandinės variantai redoks aktyviųjų terapijos priemonių, skirtų mitochondrinių ligų ir kitokių būklių gydymui ir energijos biologinių žymenų moduliavimui
EP1986636B1 (en) 2006-02-22 2013-04-24 Edison Pharmaceuticals, Inc. Phenol and 1,4-benzoquinone derivatives for use in the treatment of mitochondrial diseases
JP2010515736A (ja) 2007-01-10 2010-05-13 エジソン ファーマシューティカルズ， インコーポレイテッド エリスロポイエチン活性またはトロンボポイエチン活性を有する化合物を用いる呼吸鎖障害の治療
DK2220030T3 (en) 2007-11-06 2016-04-11 Edison Pharmaceuticals Inc 4- (P-QUINONYL) -2-HYDROXYBUTANAMIDDERIVATER TO TREAT mitochondrial
EP2242506A4 (en) 2008-01-07 2011-12-28 Janssen Biotech Inc METHOD FOR THE TREATMENT OF ERYTHROPOIETIN HYPORESPONSE ANIMALS
EP2237664A4 (en) 2008-01-08 2013-05-22 Edison Pharmaceuticals Inc (HET) ARYL-p-CHINONE DERIVATIVES FOR THE TREATMENT OF OCHONDRIAL DISEASES
CA2717741C (en) 2008-03-05 2018-04-03 Edison Pharmaceuticals, Inc. Treatment of hearing and balance impairments with redox-active therapeutics
EP2262508B1 (en) 2008-03-05 2018-10-03 BioElectron Technology Corporation SUBSTITUTED-p-QUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISEASES
US20110142834A1 (en) 2008-05-15 2011-06-16 Edison Pharmaceuticals, Inc. Treatment of hearing and balance impairments using compounds having erythropoietin activity
CA2724841A1 (en) 2008-05-22 2009-11-26 Edison Pharmaceuticals, Inc. Treatment of mitochondrial diseases with an erythropoietin mimetic
CA2729227C (en) 2008-06-25 2018-05-22 Andrew W. Hinman 2-heterocyclylaminoalkyl-(p-quinone) derivatives for treatment of oxidative stress diseases
US20100010100A1 (en) 2008-07-09 2010-01-14 Hinman Andrew W Dermatological compositions with anti-aging and skin even-toning properties
US20100029784A1 (en) 2008-07-30 2010-02-04 Hinman Andrew W Naphthoquinone compositions with anti-aging, anti-inflammatory and skin even-toning properties
US20100029706A1 (en) 2008-07-30 2010-02-04 Edison Parmaceuticals, Inc. a Delaware Corporation HYDROGENATED PYRIDO[4,3-b]INDOLES FOR THE TREATMENT OF OXIDATIVE STRESS
MX363223B (es) 2008-09-10 2019-03-15 Bioelectron Tech Corp Tratamiento de trastornos generalizados del desarrollo con terapeuticos con actividad redox.
CA2740773A1 (en) 2008-10-14 2010-04-22 Edison Pharmaceuticals, Inc. Treatment of oxidative stress disorders including contrast nephropathy, radiation damage and disruptions in the function of red cells
ES2553557T3 (es) 2008-10-28 2015-12-10 Edison Pharmaceuticals, Inc. Proceso para la producción de alfa-tocotrienol y derivados
WO2010126910A1 (en) 2009-04-28 2010-11-04 Edison Pharmaceuticals, Inc. Topical, periocular, or intraocular use of tocotrienols for the treatment of ophthalmic diseases
PL2424495T3 (pl) 2009-04-28 2018-06-29 Bioelectron Technology Corporation Leczenie dziedzicznej neuropatii nerwów wzrokowych lebera i dominującego zaniku nerwu wzrokowego chinonami tokotrienolu
US20100273892A1 (en) 2009-04-28 2010-10-28 Miller Guy M Formulations of tocotrienol quinones for the treatment of ophthalmic diseases
EA201200054A1 (ru) 2009-06-25 2012-05-30 Эмпэр Лайф Сайнсиз, Инк. Лечение токотриенолами или экстрактами, богатыми токотриенолами, первазивных расстройств развития
HUE037592T2 (hu) 2009-08-26 2018-09-28 Bioelectron Tech Corp Eljárások cerebrális ischemia megelõzésére és kezelésére
WO2011041452A2 (en) 2009-10-01 2011-04-07 Ampere Life Sciences, Inc. Mouse model for identifying compounds for the treatment of oxidative stress
EP2519232A1 (en) 2009-12-31 2012-11-07 Edison Pharmaceuticals, Inc. Treatment of leigh syndrome and leigh-like syndrome with tocotrienol quinones
WO2011113018A1 (en) 2010-03-12 2011-09-15 Ampere Life Sciences, Inc. Measurement and control of biological time
EA201201374A1 (ru) 2010-04-06 2013-04-30 Эдисон Фармасьютикалз, Инк. Лечение атаксии-телеангиэктазии
AU2011245384C1 (en) 2010-04-27 2016-09-01 Bioelectron Technology Corporation Formulations of quinones for the treatment of ophthalmic diseases
WO2012009271A1 (en) 2010-07-14 2012-01-19 Penwest Pharmaceuticals Co. Methods of providing anticoagulation effects in subjects
US20140031432A1 (en) 2010-08-06 2014-01-30 Ampere Life Sciences, Inc. Treatment of mitochondrial diseases with vitamin k
US20130345312A1 (en) 2010-08-06 2013-12-26 Orion D. Jankowski Treatment of mitochondrial diseases with naphthoquinones
WO2012068552A1 (en) 2010-11-19 2012-05-24 Edison Pharmaceuticals, Inc. Methods for improving blood glucose control
AU2012240263B2 (en) 2011-04-04 2017-04-13 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Arizona State University Multifunctional radical quenchers for the treatment of mitochondrial dysfunction
CA2865316A1 (en) 2011-04-28 2012-11-01 Gino Cortopassi Agents useful for treating friedreich's ataxia and other neurodegenerative diseases
WO2012154613A1 (en) 2011-05-06 2012-11-15 Edison Pharmaceuticals, Inc. Improved process for the preparation of d-alpha-tocotrienol from natural extracts
US8980884B2 (en) * 2011-06-01 2015-03-17 Wisconsin Alumni Research Foundation Methods for treating Alzheimer's disease
WO2012170773A1 (en) 2011-06-08 2012-12-13 Edison Pharmaceuticals, Inc. Adjunctive therapy for the treatment of mitochondrial disorders with quinones and naphthoquinones
US9464016B2 (en) 2011-06-14 2016-10-11 Edison Pharmaceuticals, Inc. Catechol derivatives for treatment of oxidative stress diseases
WO2013006736A1 (en) 2011-07-06 2013-01-10 Edison Pharmaceuticals, Inc Treatment of leigh syndrome and leigh-like syndrome, including complications of sucla2 mutations, with tocotrienol quinones
WO2013006737A1 (en) 2011-07-06 2013-01-10 Edison Pharmaceuticals, Inc. Treatment of methylmalonic aciduria, isovaleric aciduria, and other organic acidurias with tocotrienol quinones
JP2014520894A (ja) 2011-07-19 2014-08-25 エジソン ファーマシューティカルズ， インコーポレイテッド 非アルファトコトリエノールの存在下でのアルファトコトリエノールの選択的酸化のための方法
EP2892516A1 (en) 2012-09-07 2015-07-15 Edison Pharmaceuticals, Inc. Quinone derivatives for use in the modulation of redox status of individuals

Also Published As

Publication number Publication date
US9296712B2 (en) 2016-03-29
JP2016515527A (ja) 2016-05-30
CA2906150A1 (en) 2014-09-18
WO2014145118A1 (en) 2014-09-18
US20140275054A1 (en) 2014-09-18
EP2970238A1 (en) 2016-01-20

Similar Documents

Publication Publication Date Title
HK1220449A1 (zh) 治疗氧化应激障碍的试卤灵衍生物
HK1220450A1 (zh) 治疗氧化应激障碍的吩嗪-3-酮和吩噻嗪-3-酮衍生产品
HK1220451A1 (zh) 用於治疗氧化应激障碍的烷基-杂芳基取代醌衍生物
HK1223369A1 (zh) 用於治疗氧化应激障碍的羧酸衍生物
WO2009111576A3 (en) 2-SUBSTITUTED-p-QUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISEASES
EP3099380A4 (en) Methods and compositions for killing senescent cells and for treating senescence-associated diseases and disorders
EP3413852A4 (en) METHOD, COMPOSITIONS AND DEVICES FOR TREATING PSORIASIS BY PHOTOTHERAPY
EP3119913A4 (en) Methods and compositions for treatment of immune-related diseases or disorders and/or therapy monitoring
PH12015502153B1 (en) Compositions, formulations and methods for treating ocular diseases
AU2015237050A8 (en) Quinoline derivatives as SMO inhibitors
MX391378B (es) Derivados de fluoroalquil-, fluoroalcoxi-, fenoxi-, heteroariloxi-, alcoxi- y amina-1,4-benzoquinona para tratamiento de trastornos de estres oxidativo.
EP3096617A4 (en) Compositions and methods for treating ocular diseases
LT3169328T (lt) Chinolino dariniai, skirti uždegiminių ligų gydymui
EP3347000A4 (en) METHODS OF TREATING DISORDERS AND SKIN DISORDERS USING HAPTENES
EP3294418A4 (en) Targeted selection of patients for treatment with cortistatin derivatives
EP3503906A4 (en) METHODS FOR THE TREATMENT OF DISORDERS ASSOCIATED WITH BILAR ACIDS
EP2967049A4 (en) Methods, compounds, and compositions for the treatment of angiotensin-related diseases
WO2014151456A3 (en) Treatment of inflammatory diseases
EP3104852A4 (en) Compositions and methods for treating aging and age-related diseases and symptoms
EP3554505A4 (en) METHODS FOR TREATMENT OF EYE DISEASES
EP3253401A4 (en) Method of treating diseases
EP3340974A4 (en) METHODS OF TREATING DISEASES
EP3240577A4 (en) Methods and compositions for treating brain diseases
EP3364965A4 (en) METHOD AND COMPOSITIONS FOR TREATING NEURODEEGENERATIVE DISEASES
EP3182992A4 (en) Methods of treating mild brain injury